Delirium Market: Growth Analysis: Trends, Innovations, and Future Projections (2025–2032)

The Delirium Market size was valued at USD 348 Million in 2024 and is expected to reach USD 522 Million by 2032, exhibiting a compound annual growth rate (CAGR) of 5.45% during the forecast period (2025-2032).
Global Delirium Market Overview:
Delirium is a sudden disruption in mental state, marked by confusion, disorientation, and difficulty concentrating, often triggered by underlying medical conditions or medications. It is commonly associated with prolonged or severe illnesses, bodily imbalances such as low sodium, infections, surgery, certain medications, and substance use or withdrawal. Symptoms include sudden confusion, memory impairment, difficulty concentrating, hallucinations, restlessness, agitation, and unusual vocalizations. While delirium occur at any age, it is most prevalent in older adults, particularly those over 65, and less common in younger individuals unless they are critically ill, post-surgical, or have underlying medical conditions. It is triggered by trauma, surgery, infection, and sepsis, all of which share common pathogenetic mechanisms. Healthcare professionals diagnose delirium through medical history evaluation, physical and neurological examinations, and tests such as blood work, urine analysis, and brain imaging to identify underlying causes.

The increasing prevalence of neurological disorders, linked to genetic defects, congenital abnormalities, and nerve injuries, is driving market expansion. Standardized assessment tools like the Confusion Assessment Method and Delirium Observation Screening Scale have enhanced diagnostic accuracy, enabling non-psychiatric clinicians to efficiently identify the condition. Additionally, advancements in targeted therapies and innovative treatments are fueling Delirium Market growth.To know about the Research Methodology :- Request Free Sample Report

The adoption of biomarkers, including neurofilament light chain (NfL), inflammatory cytokines, and tau proteins, has improved early screening and risk stratification. Emerging digital and AI-based tools, such as cognitive testing, wearable devices, mobile applications, and predictive algorithms, are transforming delirium management by enhancing monitoring and diagnosis. EEG-based diagnostics, supported by portable EEG devices and machine learning, enable rapid bedside detection, particularly in critical care and geriatric settings. A key focus in delirium treatment is addressing neuroinflammation, with research identifying inflammatory pathways such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) as major contributors. Anti-inflammatory and immune-modulating therapies are under development to mitigate cognitive decline, while cholinesterase inhibitors are gaining recognition for their role in neurotransmitter balance. Additionally, glutamate modulators and GABA agonists are being explored for their potential to regulate brain function and alleviate delirium severity.

The Asia-Pacific region is poised for rapid growth from 2025 to 2032, driven by advancements in healthcare and IT, the expansion of the health and wellness sector, and increased investments in behavioral healthcare services. The continued integration of digital health technologies, biomarker research, and AI-driven diagnostic tools enhance early detection and treatment outcomes, ultimately reducing the healthcare burden associated with delirium. As Delirium key players invest in innovative therapies and personalized treatment approaches, the delirium market is expected to witness sustained growth and transformation in the coming years.
Global Delirium Market Dynamics
Growth Drivers and Market Trends in the Delirium Sector: Impact of Aging Population and Advancements in Diagnosis and Treatment:

The delirium market is experiencing significant growth, primarily driven by the rising aging population and advancements in diagnostic technologies therapeutic options, and early detection tools. The aging global population is a key driver, as older adults are more susceptible to delirium due to factors like cognitive decline, polypharmacy, frequent hospitalizations, and age-related physiological changes such as neurotransmitter alterations. The WHO projects that the population aged 60+ grow from 1 billion in 2025 to 1.8 billion by 2030 and 2.1 billion by 2050, with the number of people aged 80+ increasing by 476 million between 2025 and 2050. This demographic shift fuels the demand for diagnostic tools, treatment strategies, and specialized geriatric care programs, which significantly boost the Delirium Market growth.

January 7, 2019: Dr. Lata McGinn, Cognitive Behavioural Consultant and Professor at Yeshiva University, announced the launch of the New International Cognitive Behaviour Therapy Organization. The organization is dedicated to the promotion of health and well-being through the scientific development and implementation of evidence-based cognitive behavioral strategies designed to evaluate, prevent, and treat mental conditions and illnesses.

Furthermore, the increasing prevalence of neurological disorders, such as those caused by genetic defects, congenital abnormalities, and nerve injuries, is also contributing to the rise in delirium cases. The use of antipsychotics and benzodiazepines to manage symptoms such as agitation and hallucinations, as well as the growth in cognitive testing methods like MMSE and standardized tools such as CAM and DOSS, are further fueling market expansion. Despite these advancements, the market faces challenges in terms of research and development costs, regulatory hurdles, and the need for widespread awareness and training among clinicians. Additionally, the complexity of delirium’s pathophysiology and its overlap with other cognitive disorders makes accurate diagnosis and treatment a challenge. These factors may hinder the pace of market growth.

Challenges and Market Dynamics in Delirium: Impact of Neurological Disorders, Treatment Approaches, and Diagnostic Complexities:

Recent advancements in early detection and diagnostic technologies are opening new opportunities in the market. Innovations like biomarker studies, digital cognitive tests, and AI-based tools are transforming clinical decision-making and enhancing early intervention. Biomarkers such as neurofilament light chain (NfL), inflammatory cytokines, and tau proteins are enabling molecular-level detection, while wearable devices and mobile apps allow real-time monitoring. AI-driven diagnostic algorithms and portable EEG equipment are enhancing diagnosis accuracy and enabling rapid bedside detection. These advancements are improving outcomes, driving market growth, and reducing the healthcare burden.

Advancements in Delirium Treatment: Emerging Therapies and Personalized Medicine Approaches:

Moreover, the development of new therapies targeting delirium’s complex pathophysiology is boosting market opportunities. Key developments include neuroprotective agents, targeted drugs, and personalized medicine, which are improving treatment outcomes. Drugs targeting neuroinflammation, such as those addressing IL-6 and TNF-α pathways, are showing promise in preventing cognitive decline. Other drugs like cholinesterase inhibitors, glutamate modulators, and GABA agonists are being explored to balance brain function and reduce delirium intensity. Additionally, the repurposing of drugs for Alzheimer’s, Parkinson’s, and schizophrenia, combined with AI-driven precision medicine, is accelerating research and advancing treatment strategies.


Global Delirium Market Segmentation By Type:

The Delirium Market is segmented by type into Hyperactive, Hypoactive, and Mixed. In 2024, the Hypoactive segment is expected to dominate the market due to its subdued motor activity, which requires specialized interventions. Advances in pharmaceuticals and targeted therapies are driving innovation, offering new treatment options. Increasing recognition of the importance of early detection and tailored care for hypoactive delirium is further contributing to market growth.

Global Delirium Market Segmentation by Diagnosis and Treatment:

The Delirium Market is segmented by Diagnosis and Treatment. The Diagnosis segment led the market in 2024 and is expected to grow the fastest from 2025 to 2032. The integration of AI and machine learning in diagnostics is enhancing efficiency and accuracy, driving early detection and intervention, which fuels research and development investments.

Global Delirium Market Segmentation By End Users:

The market is also segmented by End-User, including Hospitals, Specialty Care, and Research Centers. Hospitals dominated the market in 2024, with homecare expected to be the fastest-growing segment during 2025-2032. Hospitals are increasingly prioritizing delirium management, driven by an aging population and its impact on healthcare outcomes. Investments in staff training, awareness programs, and specialized delirium protocols are improving patient care and supporting market growth.
Global Delirium Market Regional Analysis :
The global delirium market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World, with North America leading the market in 2024. This dominance is attributed to the region’s aging population, rising prevalence of chronic diseases, and growing awareness of delirium as a critical component of patient care. North America's advanced healthcare infrastructure and strong medical research focus are key drivers supporting diagnostic and therapeutic advancements for delirium management. Healthcare institutions in the region are actively implementing specialized protocols, clinician training programs, and cutting-edge technologies to enhance early detection and treatment.

Europe holds the second-largest market share, with Germany leading the region. France, however, is the fastest-growing market in Europe, driven by favorable health policies and integrated healthcare services. In the Asia-Pacific region, the delirium industry is set for rapid growth from 2025 to 2032 due to increasing healthcare investments, improving infrastructure, and greater awareness. China dominates in Delirium market share, while India experiences the fastest growth within the region.

Delirium Key countries analyzed in the delirium market include the United States, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. During the COVID-19 pandemic, Canada saw delirium incidence range between 35.9 to 41.4 per 1,000 patients, highlighting the urgent need for improved management strategies. In India, a study in the southern region reported a 12.69% prevalence of delirium among the elderly, with hypertension identified as a significant risk factor. Meanwhile, in the United States, the Society of Critical Care Medicine emphasizes the importance of early diagnosis, underlining its role in rapidly identifying underlying causes, evaluating treatment efficacy, and optimizing patient outcomes.

As the global healthcare landscape evolves, regional disparities in awareness, access to care, and technological adoption will continue to influence market dynamics. However, increasing investment in delirium research, education, and healthcare innovations across all regions is expected to drive long-term Delirium Market growth.
Global Delirium Market Competitive Landscape
Suvorexant, manufactured by Merck & Co., acts as an antagonist of the Orexin receptor type 1 and Orexin receptor type 2. It is primarily administered through the oral route. CN-105, manufactured by CereNova, is an Apolipoprotein E agonist and is mainly administered through the intravenous route.

In April 2023, Otsuka Pharmaceutical Co., Ltd. (Japan) obtained approval from the U.S. Food and Drug Administration (FDA) for ABILIFY ASIMTUFII (aripiprazole). This medication is authorized for the treatment of schizophrenia, and delirium, and as a maintenance monotherapy for individuals with bipolar I disorder. Furthermore, it is beneficial in alleviating symptoms associated with delirium.
Delirium Market Scope: Inquire Before Buying



Global Delirium Market


Report Coverage
Details


Base Year:
2024
Forecast Period:
2025-2032


Historical Data:
2019 to 2024
Market Size in 2024:
USD 348 Mn.


Forecast Period 2025 to 2032 CAGR:
5.45%
Market Size in 2032:
USD 522 Mn.


 Segments Covered:
by Type
Hyperactive
Hypoactive
Mixed Source


by Diagnosis
Laboratory Tests
Physical Examination
Imaging test


by Treatment
Antipsychotics
Susupportive care


by End-User
Hospitals
Speciality Care
Research Centers



Global Delirium Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Russia and Rest of Europe)
Asia Pacific (China, S. Korea, India, Japan, Australia, Indonesia, Malaysia, Philippians, Thailand, Vietnam, Rest of Asia Pacific)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria, Rest of MEA)
South America (Brazil, Argentina, Colombia, Chile, Rest of South America)
Global Delirium Market Key Players includes:
1. Otsuka Pharmaceutical Co., Ltd (Japan)
2. Mylan N.V (US)
3. Teva Pharmaceutical Industries Ltd (Israel)
4. Zydus Group (India)
5. Glenmark Pharmaceuticals Ltd (India)
6. Pfizer (India)
7. Novartis AG (Switzerland)
8. Ceribell, Inc. (United States)
9. Koninklijke Philips N.V. (Netherlands)
10. AbbVie Inc. (United States)
11. Sanofi (France)
12. Viatris Inc. (United States)
13. Sandoz Inc. (Switzerland)
14. Apotex Inc. (Canada)
15. Johnson & Johnson (United States)
16. Glenmark Pharmaceuticals Ltd. (India)
17. ABneal Pharmaceutical LLC (United States)
18. H. Lundbeck A/S (Denmark)
19. Eli Lilly and Company (United States)
20. GlaxoSmithKline plc (United Kingdom)
21. Fraser Healthcare (United States)
22. AstraZeneca (United Kingdom)
23. Bristol-Myers Squibb Company (United States)
24. Dr. Reddy's Laboratories Ltd (India)
25. Endo International plc (Ireland)
26. Sun Pharmaceutical Industries Ltd (India)
27. Lupin Limited (India)
28. Cipla Inc. (India)
29. Acadia Pharmaceuticals Inc. (United States)
30. Bayer AG (Germany)
31. Boehringer Ingelheim (Germany)
Frequently Asked Questions:
1. Which region has the largest share in the Global Delirium Market Market?
Ans: North America and the European region region held the highest share in 2024.

2. What is the growth rate of the Global Delirium Market Market?
Ans: The Global Delirium Market Market is growing at a CAGR of 5.45% during the forecasting period 2025-2032.

3. Who are the key players in the Global Delirium Market Market?
Ans: The important key players in the Global Delirium Market Market are – Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Novartis AG (Switzerland), Ceribell, Inc. (United States), Koninklijke Philips N.V. (Netherlands)

4. What is the study period of this Market?
Ans: The Global Delirium Market Market is studied from 2024 to 2032.